AMICUS THERAPEUTICS, INC. — Director's Dealing 2017

Oct 20, 2017

SEC Form 4/A — Form 4/A

Issuer: AMICUS THERAPEUTICS INC (FOLD)
CIK: 0001178879
Period of Report: 2017-10-17

Reporting Person: Crowley John F (Director, Chairman & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-10-17	Common Stock	M	52722	$14.75	Acquired	380723	Direct
2017-10-17	Common Stock	S	52722	$14.75	Disposed	328001	Direct
2017-10-18	Common Stock	M	19013	$14.7503	Acquired	347014	Direct
2017-10-18	Common Stock	S	19013	$14.7503	Disposed	328001	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-10-17	Stock Options (right to buy)	$3.53	M	52722	Disposed	2023-01-28	Common Stock (52722)	Direct
2017-10-18	Stock Options (right to buy)	$3.53	M	19013	Disposed	2023-01-28	Common Stock (19013)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	64895	Direct

Footnotes

F1: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017.

F2: This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.75 to $14.79. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

F3: This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.75 to $14.79. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.